Which has stronger valuation & earnings, LFMD or SERA?

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $193.33M 0.93 $14.35M $0.05 74.20 Sera Prognostics $57K 1,408.35 -$31.93M -$0.65 N/A

Is LFMD or SERA more profitable?

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Sera Prognostics -56,385.97% -41.02% -30.95%

Is SERA or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% Biodesix -33.26% -2,101.40% -35.65%

Which has better earnings and valuation, XGN or SERA?

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $68.38M 1.65 -$19.95M -$0.89 N/A Sera Prognostics $57K 1,408.35 -$31.93M -$0.65 N/A

Is XGN or SERA more profitable?

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% Sera Prognostics -56,385.97% -41.02% -30.95%

Do analysts rate BNR or SERA?

Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 168.29%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Sera Prognostics (SERA) Competitors

$2.05 -0.12 (-5.53%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.04 -0.01 (-0.49%)

As of 07/24/2026 07:34 PM Eastern

Compare

SERA vs. SBC, LFMD, BDSX, XGN, and BNR

Should you buy Sera Prognostics stock or one of its competitors? MarketBeat compares Sera Prognostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sera Prognostics include SBC Medical Group (SBC), LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry.

How does Sera Prognostics compare to SBC Medical Group?

Sera Prognostics (NASDAQ:SERA) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Sera Prognostics presently has a consensus price target of $5.50, suggesting a potential upside of 168.29%. SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 177.78%. Given SBC Medical Group's higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SBC Medical Group had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for SBC Medical Group and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.89 beat SBC Medical Group's score of 0.44 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Overall Sentiment
Sera Prognostics	Very Positive
SBC Medical Group	Neutral

SBC Medical Group has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$57K	1,408.35	-$31.93M	-$0.65	N/A
SBC Medical Group	$169.34M	1.85	$50.99M	$0.39	7.85

SBC Medical Group has a net margin of 24.09% compared to Sera Prognostics' net margin of -56,385.97%. SBC Medical Group's return on equity of 15.90% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
SBC Medical Group	24.09%	15.90%	11.61%

Sera Prognostics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 81.7% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SBC Medical Group beats Sera Prognostics on 12 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$193.33M	0.93	$14.35M	$0.05	74.20
Sera Prognostics	$57K	1,408.35	-$31.93M	-$0.65	N/A

LifeMD currently has a consensus target price of $9.14, suggesting a potential upside of 146.44%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 168.29%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, LifeMD had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 4 mentions for LifeMD and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.89 beat LifeMD's score of 0.51 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Positive
Sera Prognostics	Very Positive

LifeMD has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Summary

LifeMD beats Sera Prognostics on 10 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Biodesix?

Sera Prognostics (NASDAQ:SERA) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Biodesix	-33.26%	-2,101.40%	-35.65%

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sera Prognostics has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$57K	1,408.35	-$31.93M	-$0.65	N/A
Biodesix	$96.10M	2.37	-$35.26M	-$4.06	N/A

Sera Prognostics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

In the previous week, Biodesix had 4 more articles in the media than Sera Prognostics. MarketBeat recorded 5 mentions for Biodesix and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.89 beat Biodesix's score of 0.98 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Overall Sentiment
Sera Prognostics	Very Positive
Biodesix	Positive

Sera Prognostics currently has a consensus price target of $5.50, suggesting a potential upside of 168.29%. Biodesix has a consensus price target of $28.33, suggesting a potential upside of 28.79%. Given Sera Prognostics' higher probable upside, research analysts plainly believe Sera Prognostics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Sera Prognostics beats Biodesix on 10 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Exagen?

Exagen (NASDAQ:XGN) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

75.3% of Exagen shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Exagen presently has a consensus price target of $9.11, suggesting a potential upside of 94.68%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 168.29%. Given Sera Prognostics' higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$68.38M	1.65	-$19.95M	-$0.89	N/A
Sera Prognostics	$57K	1,408.35	-$31.93M	-$0.65	N/A

In the previous week, Exagen had 2 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Exagen and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.89 beat Exagen's score of 0.63 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Positive
Sera Prognostics	Very Positive

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

Exagen beats Sera Prognostics on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Burning Rock Biotech has higher revenue and earnings than Sera Prognostics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.18	-$7.92M	-$0.82	N/A
Sera Prognostics	$57K	1,408.35	-$31.93M	-$0.65	N/A

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Burning Rock Biotech had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for Burning Rock Biotech and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 1.89 beat Burning Rock Biotech's score of 1.68 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Sera Prognostics	Very Positive

Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 168.29%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Burning Rock Biotech has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Burning Rock Biotech has a net margin of -11.57% compared to Sera Prognostics' net margin of -56,385.97%. Burning Rock Biotech's return on equity of -10.98% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Summary

Sera Prognostics beats Burning Rock Biotech on 9 of the 17 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$80.28M	$9.51B	$6.87B	$12.26B
Dividend Yield	N/A	1.64%	2.67%	9.79%
P/E Ratio	-3.15	25.73	27.11	23.64
Price / Sales	1,408.35	26.23	512.89	89.27
Price / Cash	N/A	142.74	50.54	59.64
Price / Book	1.06	6.11	10.28	6.07
Net Income	-$31.93M	$179.69M	$3.60B	$331.99M
7 Day Performance	N/A	-3.06%	-1.27%	-0.63%
1 Month Performance	13.89%	0.49%	-0.37%	-2.00%
1 Year Performance	-36.92%	9.52%	18.30%	13.62%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	3.5975 of 5 stars	$2.05 -5.5%	$5.50 +168.3%	-36.9%	$80.28M	$57K	N/A	120	Positive News
SBC SBC Medical Group	3.243 of 5 stars	$2.98 -2.0%	$8.50 +185.2%	-37.2%	$311.83M	$169.34M	7.64	N/A	Short Interest Increase Gap Down
LFMD LifeMD	2.8611 of 5 stars	$4.09 -5.3%	$9.14 +123.5%	-65.2%	$208.93M	$194.05M	81.82	230	News Coverage
BDSX Biodesix	3.689 of 5 stars	$21.14 +6.7%	$28.33 +34.0%	+163.3%	$205.15M	$96.10M	N/A	220	News Coverage
XGN Exagen	2.7749 of 5 stars	$4.86 +3.8%	$9.11 +87.5%	-35.2%	$113.07M	$66.57M	N/A	220	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. SBC, LFMD, BDSX, XGN, and BNR

How does Sera Prognostics compare to SBC Medical Group?

Summary

How does Sera Prognostics compare to LifeMD?

Summary

How does Sera Prognostics compare to Biodesix?

Summary

How does Sera Prognostics compare to Exagen?

Summary

How does Sera Prognostics compare to Burning Rock Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. SBC, LFMD, BDSX, XGN, and BNR

How does Sera Prognostics compare to SBC Medical Group?

Do analysts prefer SERA or SBC?

Does the media prefer SERA or SBC?

Which has higher valuation & earnings, SERA or SBC?

Is SERA or SBC more profitable?

Which has more risk and volatility, SERA or SBC?

Do institutionals and insiders hold more shares of SERA or SBC?

Summary

How does Sera Prognostics compare to LifeMD?

Do insiders and institutionals hold more shares of LFMD or SERA?

Which has stronger valuation & earnings, LFMD or SERA?

Do analysts rate LFMD or SERA?

Does the media favor LFMD or SERA?

Which has more volatility & risk, LFMD or SERA?

Is LFMD or SERA more profitable?

Summary

How does Sera Prognostics compare to Biodesix?

Is SERA or BDSX more profitable?

Do institutionals & insiders hold more shares of SERA or BDSX?

Which has higher earnings & valuation, SERA or BDSX?

Which has more risk & volatility, SERA or BDSX?

Does the media refer more to SERA or BDSX?

Do analysts prefer SERA or BDSX?

Summary

How does Sera Prognostics compare to Exagen?

Do insiders and institutionals hold more shares of XGN or SERA?

Do analysts prefer XGN or SERA?

Which has better earnings and valuation, XGN or SERA?

Does the media refer more to XGN or SERA?

Is XGN or SERA more profitable?

Which has more risk & volatility, XGN or SERA?

Summary

How does Sera Prognostics compare to Burning Rock Biotech?

Which has preferable valuation & earnings, BNR or SERA?

Do insiders & institutionals believe in BNR or SERA?

Does the media prefer BNR or SERA?

Do analysts rate BNR or SERA?

Which has more volatility and risk, BNR or SERA?

Is BNR or SERA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools